[ad_1]
AstraZeneca shares fall 5% on disappointing lung cancer drug trial
AstraZeneca shares fell more than 5% Tuesday morning, the biggest one-day drop in seven months, after the British pharmaceutical giant announced disappointing lung cancer drug trial results.
The Covid-19 vaccine maker was trading at the bottom of the FTSE 100 and dragged the wider healthcare sector lower after data published Monday showed that its experimental drug did not significantly improve overall survival results for patients.
Share were down 4.9% by 9:43 a.m. London time.
This is a breaking news story. Please check back for updates.
[ad_2]
Source link
#AstraZeneca #shares #fall #disappointing #lung #cancer #drug #trial